These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33441921)

  • 1. Aberrant serum parathyroid hormone, calcium, and phosphorus as risk factors for peritonitis in peritoneal dialysis patients.
    Liao CT; Zheng CM; Lin YC; Wu MY; Lin YF; Hsu YH; Hsu CC; Wu MS
    Sci Rep; 2021 Jan; 11(1):1171. PubMed ID: 33441921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International variations in serum PTH and calcium levels and their mortality associations in peritoneal dialysis patients: Results from PDOPPS.
    Nitta K; Bieber B; Karaboyas A; Johnson DW; Kanjanabuch T; Kim YL; Lambie M; Hartman J; Shen JI; Naljayan M; Pecoits-Filho R; Robinson BM; Pisoni RL; Perl J; Kawanishi H
    Perit Dial Int; 2024 Jul; 44(4):275-286. PubMed ID: 38501163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients.
    Navarro JF; Mora C; Macia M; Garcia J
    Perit Dial Int; 1999; 19(5):455-61. PubMed ID: 11379859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors modulating cytosolic calcium. Role in lipid metabolism and cardiovascular morbidity and mortality in peritoneal dialysis patients.
    Gadallah MF; el-Shahawy M; Andrews G; Ibrahim M; Ramdeen G; Hanna D; Gorospe W; Morkos A; Abbassian M; Moles K
    Adv Perit Dial; 2001; 17():29-36. PubMed ID: 11510292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of Serum Calcium, Phosphorus, PTH and ALP on Mortality in Peritoneal Dialysis Patients: A Nationwide, Population-based Longitudinal Study Using TWRDS 2005-2012.
    Liu CT; Lin YC; Lin YC; Kao CC; Chen HH; Hsu CC; Wu MS
    Sci Rep; 2017 Feb; 7(1):33. PubMed ID: 28232731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inverse correlation between serum magnesium and parathyroid hormone in peritoneal dialysis patients: a contributing factor to adynamic bone disease?
    Wei M; Esbaei K; Bargman JM; Oreopoulos DG
    Int Urol Nephrol; 2006; 38(2):317-22. PubMed ID: 16868704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low serum parathyroid hormone is a risk factor for peritonitis episodes in incident peritoneal dialysis patients: a retrospective study.
    Yang Y; Da J; Jiang Y; Yuan J; Zha Y
    BMC Nephrol; 2021 Jan; 22(1):44. PubMed ID: 33514340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012.
    Lin YC; Lin YC; Hsu CY; Kao CC; Chang FC; Chen TW; Chen HH; Hsu CC; Wu MS;
    PLoS One; 2015; 10(6):e0129737. PubMed ID: 26107510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The differences in acid-base status and the calcium parathyroid axis between peritoneal dialysis and hemodialysis.
    Morishita M; Matsuo N; Maruyama Y; Nakao M; Yamamoto I; Tanno Y; Ohkido I; Ikeda M; Yokoyama K; Yokoo T
    Clin Nephrol; 2016 Aug; 86(2):55-61. PubMed ID: 27345183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineral and bone disorder in Chinese dialysis patients: a multicenter study.
    Kong X; Zhang L; Zhang L; Chen N; Gu Y; Yu X; Liu W; Chen J; Peng L; Yuan W; Wu H; Chen W; Fan M; He L; Ding F; Chen X; Xiong Z; Zhang J; Jia Q; Shi W; Xing C; Tang X; Hou F; Shu G; Mei C; Wang L; Xu D; Ni Z; Zuo L; Wang M; Wang H
    BMC Nephrol; 2012 Sep; 13():116. PubMed ID: 22994525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.
    Fernández-Martín JL; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Gorriz JL; Rutkowski B; Ferreira A; Bos WJ; Covic A; Rodríguez-García M; Sánchez JE; Rodríguez-Puyol D; Cannata-Andia JB;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1542-51. PubMed ID: 25920921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic kidney disease mineral bone disorder and health-related quality of life among incident end-stage renal-disease patients.
    Johansen KL; Chertow GM
    J Ren Nutr; 2007 Sep; 17(5):305-13. PubMed ID: 17720099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study.
    Naves-Díaz M; Passlick-Deetjen J; Guinsburg A; Marelli C; Fernández-Martín JL; Rodríguez-Puyol D; Cannata-Andía JB
    Nephrol Dial Transplant; 2011 Jun; 26(6):1938-47. PubMed ID: 20513773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal or low initial PTH levels are not a predictor of morbidity/mortality in patients undergoing chronic peritoneal dialysis.
    Dimkovic NB; Bargman J; Vas S; Oreopoulos DG
    Perit Dial Int; 2002; 22(2):204-10. PubMed ID: 11990405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detecting high-risk chronic kidney disease-mineral bone disorder phenotypes among patients on dialysis: a historical cohort study.
    Neri L; Kreuzberg U; Bellocchio F; Brancaccio D; Barbieri C; Canaud B; Stuard S; Ketteler M
    Nephrol Dial Transplant; 2019 Apr; 34(4):682-691. PubMed ID: 30165528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High alkaline phosphatase and low intact parathyroid hormone associate with worse clinical outcome in peritoneal dialysis patients.
    Chen Z; Zhang X; Han F; Xie X; Hua Z; Huang X; Lindholm B; Haarhaus M; Stenvinkel P; Qureshi AR; Chen J
    Perit Dial Int; 2021 Mar; 41(2):236-243. PubMed ID: 32363998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorus control in peritoneal dialysis patients.
    Yavuz A; Ersoy FF; Passadakis PS; Tam P; Evaggelos DM; Katopodis KP; Ozener C; Akçiçek F; Camsari T; Ateş K; Ataman R; Vlachojannis GJ; Dombros NA; Utaş C; Akpolat T; Bozfakioğlu S; Wu G; Karayaylali I; Arinsoy T; Stathakis CP; Yavuz M; Tsakiris DJ; Dimitriades AC; Yilmaz ME; Gültekin M; Süleymanlar G; Oreopoulos DG
    Kidney Int Suppl; 2008 Apr; (108):S152-8. PubMed ID: 18379539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis.
    Rhee CM; Molnar MZ; Lau WL; Ravel V; Kovesdy CP; Mehrotra R; Kalantar-Zadeh K
    Perit Dial Int; 2014; 34(7):732-48. PubMed ID: 24385335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.